Latest Interferon Stories
-- SVR(12) rates of 99 percent with and without ribavirin were achieved in genotype 1b patients new to treatment BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results
ResearchMoz include new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Industry Size, Shares, Growth, Trends and Forecast 2019" to its huge collection
- Ninety-nine percent SVR(12) rates with and without ribavirin in certain patient types NORTH CHICAGO, Ill., Jan.
Health and Harmony LLC now offers a natural way to increase the immune system, gain added protection against the flu, and offset the unwanted side effects that so many prescription drugs can cause
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective.
Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus (HCV) improves kidney and cardiovascular outcomes for patients with diabetes.
Sovaldi (sofosbuvir), a new drug that can treat hepatitis C infections, has been approved for sale by the US Food and Drug Administration, agency officials confirmed on Friday.
A Massachusetts General Hospital (MGH)-led research team has identified an immune cell protein that is critical to setting off the body's initial response against viral infection.
Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...
- A woman chauffeur.
- A woman who operates an automobile.